Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant docetaxel in locally advanced non-metastatic prostate cancer
2007-002909-49Phase 2Active
- Sponsor
- G.O.N.O. - Gruppo Oncologico del Nord Ovest
- Start
- Oct 2007
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and prednisone in prostate adenocarcinoma and prostate cancer (PCa), sponsored by G.O.N.O. - Gruppo Oncologico del Nord Ovest. Primary endpoint: Pathologic response rate. Started Oct 2007; status: active.
02
Drugs
docetaxelprednisone
03
Conditions
prostate adenocarcinomaprostate cancer (PCa)
Beyond the preview
Go deeper on 2007-002909-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002909-49.